AstraZeneca cancer drug hits second goal by extending survival

LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already go…
Read the full story: Reuters: Health News